Clever Culture Systems Expanded Lab Automation Footprint
The firm increased its fleet of microbiology automation instruments as pharmaceutical manufacturers scale AI-driven testing.
Updated on Oct. 1, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies more when they use AI to automate laboratory safety testing?
Clever Culture Systems has expanded the global adoption of its APAS Independence platform, which automates the reading and reporting of microbiology culture plates. The company currently supports eight major pharmaceutical customers with a total installed base of 37 instruments.
Why it matters
Automated plate reading replaces manual processes to improve microbiology data integrity and laboratory efficiency. This expansion reflects an industry-wide transition toward digitizing quality control workflows in pharmaceutical manufacturing.
The firm reports an installed base of 37 APAS Independence instruments, including 12 at AstraZeneca and three at Novo Nordisk. Clever Culture Systems projects that more than 50% of its sales in FY27 will originate from these existing customers.
The players
Clever Culture Systems
An ASX-listed (CC5) company specializing in automated microbiology diagnostic hardware and software for laboratory quality control.
AstraZeneca
A multinational pharmaceutical manufacturer focused on oncology, biopharmaceuticals, and rare disease research and production.
Novo Nordisk
A global healthcare firm specializing in diabetes care and chronic disease medication manufacturing.
The details
The APAS Independence platform uses artificial intelligence to scan and interpret microbiology culture plates, removing the need for manual inspection by lab technicians. By automating the visual classification of bacterial growth, the system creates a digitized audit trail for test results. The company typically follows a land-and-expand strategy, placing initial systems with customers before scaling deployment across their wider manufacturing networks.
Timeline
FY27: The company projects that more than 50% of its total sales will originate from existing customers.
The Tech Race
Clever Culture Systems is moving beyond early-adopter pilot programs to secure recurring revenue within large-scale pharmaceutical networks. This deployment trajectory pits the company against traditional manual lab processes as competitors race to demonstrate higher data integrity and operational throughput.
Pharmaceutical manufacturing workflows will shift toward automated, AI-verified testing as these instruments are installed. Laboratory personnel should expect improved data accuracy and faster reporting times as manual inspection processes are phased out in participating facilities.
The takeaway
Clever Culture Systems is betting that existing pharmaceutical partnerships will provide over half of its revenue by FY27. Watch for updates on the firm's progress toward its target of 100 global instrument installations to confirm the pace of industry adoption.
Further reading
For broader trends in laboratory automation, see our coverage of Biotech.
Live Poll
Do you trust pharmaceutical companies more when they use AI to automate laboratory safety testing?
